Secondary malignant neoplasm of right kidney and renal pelvis
ICD-10 C79.01 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of right kidney and renal pelvis.
C79.01 refers to the presence of metastatic cancer in the right kidney and renal pelvis, originating from a primary malignancy located elsewhere in the body. This condition indicates that cancer cells have spread to the kidney from another site, which is crucial for treatment planning and prognosis. The right kidney and renal pelvis may be affected by various types of primary cancers, including lung, breast, or colorectal cancers. The diagnosis of a secondary malignant neoplasm often involves imaging studies such as CT scans or MRIs, alongside histopathological confirmation through biopsy. Staging of the disease is essential, as it helps determine the extent of metastasis and guides therapeutic decisions. Palliative care considerations are also vital, focusing on symptom management and improving the quality of life for patients with advanced disease. Given the complexity of metastatic disease, a multidisciplinary approach is often required, involving oncologists, nephrologists, and palliative care specialists.
Detailed history of the primary cancer, staging information, and treatment plans.
Patients presenting with renal symptoms who have a known history of cancer.
Ensure that the primary cancer is well-documented to support the secondary diagnosis.
Renal function tests, imaging studies, and any interventions performed.
Management of renal complications in patients with metastatic cancer.
Focus on renal function and any potential interventions that may affect coding.
Used when a biopsy is performed to confirm metastatic disease.
Pathology report must clearly indicate the presence of metastatic cells.
Oncologists should ensure that the pathology report is linked to the diagnosis.
Accurate coding of C79.01 is essential for proper treatment planning, reimbursement, and tracking of cancer care outcomes. It ensures that patients receive appropriate management for their metastatic disease.
